Novel formulation for sustained, steady-state drug release
Lyndra Therapeutics is developing an orally administered dosage form that delivers sustained, steady-state release of one or more drugs for a week or longer while temporarily residing in the stomach. The foundation is supporting the company’s work on this new drug delivery for global health conditions in low-income countries.
-
Domain
-
Investment typeDirect equity
-
StatusActive
-
Initial investmentSeries B
-
Partnered in2019
-
Investment leadRyan Kreitzer
-
HeadquartersUSA
-
Program strategyIntegrated Development
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.